Xiaosong Wang, M.D., Ph.D. - Biography
Lester & Sue SMith Breast Center & Dan L. Duncan Cancer Center
Section of Hematology/Oncology, Department of Medicine
Department of Molecular and Cellular Biology
Education and Training:
M.D.: First hospital of China Medical University, Shenyang, China
Ph.D.: Institute of Urology & Department of Immunology, Peking University Health Science Center, Beijing, China
Michigan Center for Translational Pathology & National Center for Integrative bioinformatics, University of Michigan, Ann Arbor
Wang lab Website: http://www.bcm.edu/breastcenter/wanglab/
The advancements of high-throughput transcriptomic, genomic and deep sequencing technologies have generated a flood of data in the public domain and private warehouse. However, the laboratory discoveries based on analysis of these data have met with limited success. Innovative computational technologies that can directly address the biological and clinical problems in cancer are of high demand. The mission of our group is to apply a multiple disciplinary approach inclusive of bioinformatics, genomics, molecular and cell biology, and translational studies to detect driving genetic aberrations and qualify appropriate breast cancer targets on the basis of the state-of-art high-throughput technologies.
Our current research focus is to discover and characterize novel therapeutic targets and predictive biomarkers in breast cancer. By interrogating multidimensional genomic datasets with a drug-target database and a “concept signature” analysis we developed to reveal oncogenes (Nature Biotechnology, 2009), we nominated several oncogenes deregulated by genetic or epigenetic events as potential therapeutic targets and/or predictive biomarkers in breast cancer. Four candidate targets have been validated by our preliminary experimental and clinical data. We are investigating the clinical relevance and biological function of these targets, as well as their role in breast cancer therapeutic resistance. Part of this project has been funded by the DOD Breast Cancer Idea Award, and the Susan G. Komen for the Cure Postdoc Fellowship. We expect that our new discoveries will yield novel insights into recurring genetic and epigenetic abnormalities leading to breast cancer, and establish robust targets for effective and personalized therapies.
Baylor College of Medicine
One Baylor Plaza
Alkek Research Building N1110.03
Mail Stop BCM600
Houston, TX, 77030